MKI67 and neoplasm: In TSC1-knockdown groups, tumor cells exhibited significantly higher fluorescence intensity of proliferation marker KI67 compared to controls, while anti-PD-1 monotherapy and rapamycin treatment groups showed the lowest KI67 levels (Figure 6B).